Inventiva S.A.

NASDAQ:IVA

Biotechnology

Healthcare
$3.22 +0.42%

+$0.02 today

Market cap
$167.38M
Beta
0.88
P/E (TTM)
-5.5
EPS (TTM)
-$0.56
52W Low $2.85High $7.98

Volume 2.04M

Average 0.45M

Returns on capital

Inventiva S.A. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

1171.5%

avg 117.2%

ROIC

-64.2%

avg -288.9%

ROA

-136.7%

avg -64.5%

Analysis

ROE is currently the strongest return metric at 1171.5% versus its period average of 117.2%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Pierre Broqua

Co-FounderEUR 462.63K64——

Jean Volatier

Executive VP Finance & Corporate Social ResponsibilityEUR 399.45K61——

Jason A. Campagna

President of Research and Development & Chief Medical OfficerEUR 379.92K60——

Martine Zimmermann

Executive VP of Regulatory Affairs & Quality Assurance and Head of Regulatory AffairsEUR 253.99K57——

Andrew Obenshain

Chief Executive OfficerEUR 171.03K52——

Jennifer Nava

Chief Information Officer————

Pascaline Clerc

Executive Vice President of External and Corporate Affairs—46——

Susan Coles

Chief Legal Officer—60——

Christopher Benecchi

Chief Operating Officer—54——

Nazira Amra

Chief Commercial Strategy Officer————

Axel-Sven Malkomes

Chief Financial Officer—59——

Pamela Herbster

Chief People Officer————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A-28.3%
+168.7% (5yr)5 analysts
Net IncomeN/AN/AN/A
N/A5 analysts
EBITN/AN/AN/A
N/A5 analysts

Analysis

Recent growth has been strongest in Revenue at -28.3% over three years. Forward estimates point to Revenue at +168.7% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Inventiva S.A. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about IVA's management, answered from reported figures.

Who manages IVA?

Inventiva S.A. (IVA) lists 12 active executives. The top listed executive is Jason A. Campagna, President of Research and Development & Chief Medical Officer.